GlassScriptPhysician profile
Charles W Britt
NPI 1154497279
$909.46
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $230 · 2021: $207.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $227.97 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $137.24 | 2019-2021 | |
| Acorda Therapeutics, INC | $118.90 | 2019 | |
| Lilly USA, LLC | $92.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $71.54 | 2019 | |
| Biogen, INC. | $53.76 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $39.72 | 2021 | |
| Supernus Pharmaceuticals, INC. | $37.55 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $36.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $29.45 | 2019-2020 | |
| Boston Scientific Corporation | $24.77 | 2019 | |
| Kyowa Kirin, INC. | $23.29 | 2021 | |
| Ucb, INC. | $16.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Britt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.